Last reviewed · How we verify
N-acetylcysteine + PPI-amoxicillin-clarithromycin
This combination therapy eradicates Helicobacter pylori infection by using antibiotics to kill the bacteria while N-acetylcysteine reduces mucus viscosity and a PPI suppresses gastric acid to optimize antibiotic efficacy.
This combination therapy eradicates Helicobacter pylori infection by using antibiotics to kill the bacteria while N-acetylcysteine reduces mucus viscosity and a PPI suppresses gastric acid to optimize antibiotic efficacy. Used for Helicobacter pylori infection eradication.
At a glance
| Generic name | N-acetylcysteine + PPI-amoxicillin-clarithromycin |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Triple therapy combination (mucolytic + PPI + dual antibiotics) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
N-acetylcysteine acts as a mucolytic agent that breaks down biofilm and reduces mucus viscosity, improving antibiotic penetration. The PPI (proton pump inhibitor) reduces gastric acid, creating a more favorable pH environment for antibiotic activity and reducing acid-related damage. Amoxicillin and clarithromycin are bactericidal antibiotics that directly target and kill H. pylori cells.
Approved indications
- Helicobacter pylori infection eradication
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Headache
- Taste disturbance
- Allergic reactions (amoxicillin)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: